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Abstract
Chronic fatigue syndrome is characterised by intense fatigue, with duration of over six months and
associated to other related symptoms. The latter include asthenia and easily induced tiredness that
is not recovered after a night's sleep. The fatigue becomes so severe that it forces a 50% reduction
in daily activities. Given its unknown aetiology, different hypotheses have been considered to
explain the origin of the condition (from immunological disorders to the presence of post-
traumatic oxidative stress), although there are no conclusive diagnostic tests. Diagnosis is
established through the exclusion of other diseases causing fatigue. This syndrome is rare in
childhood and adolescence, although the fatigue symptom per se is quite common in paediatric
patients. Currently, no curative treatment exists for patients with chronic fatigue syndrome. The
therapeutic approach to this syndrome requires a combination of different therapeutic modalities.
The specific characteristics of the symptomatology of patients with chronic fatigue require a rapid
adaptation of the educational, healthcare and social systems to prevent the problems derived from
current systems. Such patients require multidisciplinary management due to the multiple and
different issues affecting them. This document was realized by one of the Interdisciplinary Work
Groups from the Institute for Rare Diseases, and its aim is to point out the main social and care
needs for people affected with Chronic Fatigue Syndrome. For this, it includes not only the view of
representatives for different scientific societies, but also the patient associations view, because they
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know the true history of their social and sanitary needs. In an interdisciplinary approach, this work
also reviews the principal scientific, medical, socio-sanitary and psychological aspects of Chronic
Fatigue Syndrome.
Background
The chronic fatigue syndrome (CFS) is fundamentally
characterized by intense fatigue of unknown cause, which
is permanent and limits the patient's functional capacity,
producing various degrees of disability.
In medical terminology, fatigue is the early onset of tired-
ness after an activity has been started; it is a sensation of
exhaustion or difficulty to carry out physical or intellec-
tual activities, without recovery after a period of rest.
Fatigue has been categorized as recent fatigue, prolonged
fatigue and chronic fatigue, according to the time of evo-
lution (less than one month, more than one month and
more than six months, respectively) [1].
It is advisable to differentiate fatigue from other medical
concepts with which the symptom is often confused: first,
from asthenia, defined as the lack of strength or feeling of
inability to carry out daily tasks, which is more intense at
the end of the day, and usually improves after a period of
sleep; second, from weakness, which is the reduction or
loss of muscular strength, and the key symptom in mus-
cular diseases.
In addition to fatigue, CFS is associated to a wide spec-
trum of symptoms, including arthralgias, muscle pain,
headaches, anxiety, depressive symptoms, cognitive disor-
ders, sleep disorders, or intolerance to physical exertion,
among the most frequent [2,3].
The little understanding of CFS aetiopathogeny, together
with the difficulties to achieve an objective and quantita-
tive assessment of the symptoms that affected patients
have, has prevented for a long time the establishment of a
diagnosis [4]. A consequence of such a problem is the
variety of names CFS is known for, including allergic
encephalomyelitis, immune dysfunction syndrome, neu-
roendocrine immune dysfunction syndrome, post viral
syndrome, Iceland disease, neurasthenia, and Royal Free
disease, among others [5].
The various criteria established in recent years have
allowed a more accurate delineation of CFS, and this has
contributed to a better understanding of its clinical pic-
ture, and potential therapeutic interventions [1].
CFS is, therefore, a complex, chronic disorder of unknown
aetiology, characterized by the presence of intense and
disabling fatigue (physical and mental), with a clinical
course and without any apparent cause, which interferes
with daily activities, does not decrease with rest, worsens
with exercise, and is usually associated to systemic, physi-
cal and neuropsychological manifestations [6,7].
The aetiology, diagnosis and therapeutic options for
chronic fatigue syndrome in adults and pediatric patients
are discussed below.
The aetiology and the pathogenic mechanisms of CFS
As the criteria for CFS diagnosis are not based on the
understanding of aetiopathogenic mechanisms, some
patients present similar clinical manifestations but are
diagnosed with other conditions because fatigue is not the
primary symptom. Some of those conditions are fibromy-
algia, irritable bowel syndrome, and temporomandibular
joint syndrome. Furthermore, in addition to sharing sev-
eral symptoms with CFS, currently available evidence sug-
gests that those diseases also share similar
pathophysiologic mechanisms [8,9].
Although the aetiology and the pathogenic mechanisms
of CFS are not fully understood, several hypotheses have
been postulated and described below, being the disorders
of the central nervous system neuromodulator the one
supported by more evidence to explain the possible path-
ogenic mechanisms involved in CFS [5].
Infectious theory
Epstein Barr virus, Candida albicans, Borrelia burgdorferi,
Enterovirus, Citomegalovirus, Human Herpesvirus, Espu-
mavirus, Retrovirus, Borna virus, Coxsackie B virus, and
hepatitis C virus (HCV) have been associated to CFS, but
their pathogenic relationship with the syndrome has not
been demonstrated [10].
Immunological theory
Although different disorders have been found in the
immune system or its function, currently there is no scien-
tific evidence to attribute the cause of this syndrome to a
primary disorder of the immune system. There are a large
number of studies on immune disorders in the CFS assess-
ing identical parameters, but they frequently yield contra-
dictory results [11-14].
Neuroendocrinological theory
Several disorders in the hypothalamic-pituitary-adrenal
axis (HPA) and in the production of related hormones
have been found in CFS, as well as a disorder of the regu-BMC Psychiatry 2009, 9(Suppl 1):S1 http://www.biomedcentral.com/1471-244X/9/S1/S1
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lating mechanisms of the autonomic nervous system. It is
currently known that the relationships between the differ-
ent parts of the nervous system are mediated by neuro-
transmitters and that their disorders lead to unbalanced
functioning of certain structures and to the development
of well known diseases. Many of the clinical features in
patients with CFS are similar to those found in patients
with fibromyalgia, and it can therefore be postulated that
the physiopathological mechanisms are probably similar
in both conditions.
In patients with fibromyalgia, the research on neurotrans-
mitter disorders has started to yield positive findings, and
it is known that different clinical manifestations will
appear according the type and the site of action of affected
neurotransmitters [8,15].
Prevalence and clinical features
It is difficult to establish the prevalence of CFS, since it
depends on the diagnostic criteria used and the study pop-
ulation. Initial research suggested a prevalence between
0.002% and 0.04%. [16,17]. However, latest epidemio-
logical studies in the USA and in the United Kingdom
show prevalence rates ranging from 0.007% to 2.5% of
the general population. [18] These rates increase up to
0.5-2.5% when the population assessed includes individ-
uals seen in primary care facilities instead of the global
population. [19] In the United Kingdom, according the
Oxford criteria [20], the prevalence in the global popula-
tion has been estimated in 0.6%. In Japan the prevalence
has been found to be 1.5% in the general popula-
tion[21,22]. Thus, the prevalence in the general popula-
tion appears to be much higher than previously indicated.
Even with strict criteria for CFS, it is estimated that
approximately 1% of the adult population experiences
this condition. Interestingly, a large part of this group
remains unrecognized by the general practitioner. A strik-
ing similarity in lifestyle pattern between SF, CF and CFS
calls for further research. [23]
CFS mainly affects young adults from 20 to 40 years,
although the symptoms also exist in childhood, adoles-
cence and in the elderly [10]. It has a 2-3 times higher
prevalence in women than in men. No evidence exists
showing that any socio-economic group is more affected
than others [5].
The typical CFS case occurs acutely, and even suddenly,
usually in a previously healthy person. Initially, fever, sore
throat, cough, muscular pain and fatigue are the typically
predominant symptoms; digestive symptoms such as
diarrhoea are less common. This initial process resolves
with intense tiredness as a sequel. The cardinal or key
symptom is fatigue, essential for diagnosing the condi-
tion. Fatigue in CFS is characterised by not being second-
ary to excessive activity, with no improvement associated
with rest and worsening with stress, and directly resulting
in persistent disability (physical and mental) [7].
The chronic symptoms develop later [24], persisting for
weeks or months. Predominant symptoms vary for the
individual patient, and include fatigue, fever or intermit-
tent dysthermia, migratory arthralgias, generalised mus-
clar pain, pharyngitis or sore throat, headache, tender
cervical or axillary lymph nodes, and other less common
symptoms.
Fatigue is usually associated to neurocognitive and sleep
disorders. Patients have difficulty in concentrating,
insomnia or hypersomnia, and occasionally depression.
Palpitations, thoracic pain, night sweating, or weight loss/
increase are less common [10].
In general, clinical evolution is characterized by regular
and even seasonal recurrences. Each outbreak can be dif-
ferent from the previous one, and periods between each
recurrence are rarely completely asymptomatic [1]. CFS's
symptomatology worsens with physical or emotional
stress, interfering or limiting previous activities (including
family, work, and social activities); in some cases, patients
may need help for their basic daily activities.
The main co-morbidity is related with psychiatric disor-
ders, such as depression or anxiety, with an approximate
incidence of 28% in the Western population [25,26].
Diagnosis
As there is no pathognomonic sign or specific test for CFS,
the diagnosis of the syndrome is clinical. Other causes of
fatigue should be ruled out, through a complete and
detailed medical history, focused on the characteristics of
fatigue, delineating its form and time of onset, duration,
triggering factors, relationship with rest and physical
activity, and the degree of limitation of the patient's regu-
lar activities. Furthermore, targeted interrogation will col-
lect the symptoms in the osteomuscular, neurovegetative
and neuropsychological domains. Thus, chronic fatigue
should be differentiated from debilitation, exercise intol-
erance, sleepiness, or loss of motivation and stamina.
The presence of psychiatric disorders (anxiety, depres-
sion) should be included in the personal history as well as
possible non-infectious precipitating factors (organo-
phosphorous insecticides, solvents, CO, multiple chemi-
cal hypersensitivity, sick building syndrome, situations
that disturb sleep, etc.), and prior history of allergies. This
information should be included to rule out other alterna-
tive diagnoses such as infections, neoplasias, depression
or sleep disorder.BMC Psychiatry 2009, 9(Suppl 1):S1 http://www.biomedcentral.com/1471-244X/9/S1/S1
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Specific exploration is required for the musculoskeletal
system (strength, reflexes and muscular tone), the neuro-
logical system (looking for any neurological deficit), the
cardiovascular and respiratory systems (anaemia and car-
diac insufficiency), the endocrinological system (thyroid
gland disorders), the immune system (tender cervical,
axillary or inguinal lymph nodes) and the gastrointestinal
system. Physical findings are usually unspecific, and a
large variety of signs can be found, such as pharyngeal
soreness, fever, tender posterior cervical or axillary lymph
nodes, muscular tenderness on palpation, and, occasion-
ally, rash.
Currently, there are no specific biological or morphologi-
cal markers to establish per se the diagnosis of the CFS,
and therefore none of the alterations that can be found are
useful for diagnosis. Diagnostic criteria basically arise as a
research requirement, but their limitations for actual clin-
ical practice must be accepted.
The Centres for Disease Control and the CFS International
Study Group proposed in 1994 an international diagnos-
tic criteria (Table 1) [27]. Their main objectives were to
increase the sensitivity of the previous classification, and
to offer a more accurate definition of the condition, in
order to achieve a more consistent clinical diagnosis and
use it as a research tool. The international criteria are
based on the fulfilment of two major criteria (chronic
fatigue causing incapacity, lasting more than 6 months,
and the exclusion of associated medical and psychiatric
conditions), as well as the concurrence of a series of crite-
ria, reducing the symptoms from 11 to 8: these criteria are
based on symptoms, particularly rheumatological and
neuropsychological symptomatology.
Diagnostic protocol for patients with suspected CFS
Figure 1 details the algorithm for CFS diagnosis [28]. Con-
ditions that exclude the diagnosis of CFS are: psychiatric
disorders, such as major depression, schizophrenia, eating
disorders (anorexia, bulimia), bipolar disorder, alcohol or
other substance abuse, in addition to morbid obesity, and
active medical diseases, either non-treated or without a
completely established resolution.
Prognosis
There is an average time of 5 years from the beginning of
the symptoms to the diagnosis of the syndrome, with total
recovery rates between 0% and 37%, and improvement
between 6% and 63% [29]. Younger patients and those
without concomitant psychiatric diseases show the best
prognosis, although other studies have estimated that the
rates for both groups are similar [30].
Assessment methods
There is no single tool for the assessment of patients with
CFS that allows a global appraisal of the clinical manifes-
tations and the impact of the disease on patients. There
are specific questionnaires, according the feature to be
measured, that can provide useful information on specific
issues. A summary of them can be found in the systematic
review by Bagnall et al [31]. However, the most useful way
of collecting information is with interviews and patient
Table 1: Diagnostic criteria for chronic fatigue syndrome
1.-Persistent chronic fatigue (at least 6 months) or intermittent, unexplained chronic fatigue, which relapses, or with a definite start, and is not the 
result of recent exertions. Does not improve with rest. Results in a significant reduction in the patient's previous normal activity.
2.-Exclusion of other diseases that may cause chronic fatigue.
Four of the following minor criteria (signs or symptoms) must be present concurrently for six months or longer, after the onset of fatigue:
Minor criteria
(Signs and symptoms)
1-Recently impaired memory or concentration.
2.-Odynophagia
3.-Painful axilar or cervical adenophatias
4.-Myalgias
5.-polyartralgias without phlogosis
6.-Headache with a new pattern or seriousness.
7.-sleep which does not improve by resting.
8.-Discomfort post effort > 24 hs.BMC Psychiatry 2009, 9(Suppl 1):S1 http://www.biomedcentral.com/1471-244X/9/S1/S1
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diaries. Interview can include patient self-records, ques-
tionnaires and scales for functional assessment, such as
"Karnofsky Performance Scale, Medical Outcomes Study
Short-Form General Health Survey" (SF-36®) [32] and
Sickness Impact Profile (SIP) [33]. Interviews should be
repeated periodically in time.
Self-records and scales are excellent references and help
the therapist to assess the patient's daily activities, general
functioning and the degree of disability.
The scale is useful for the patient because they can fill in a
hierarchy/severity scale their symptoms during the initial
Diagnostic protocol for patients with suspected CFS Figure 1
Diagnostic protocol for patients with suspected CFS.
 
FATIGUE 
Medical history: History-taking and physical examination
Basic Complementary Tests
- 
 
NO 
 
NO 
NO  
NO  
NO  
NO  
Chronic fatigue and relapses 
(physical and mental) during six 
months or more.
NO  
yes
yes
yes
yes
Less than six months: Acute 
or self-limited fatigue.
Prolonged fatigue.
Periodic health evaluation.
During all the lifetime: 
Depression, other causes.
Daily tasks, style and quality of 
life significantly affected.
Idiophatic chronic asthenia.
Periodic health evaluations.
Is there any exclusion causes?
Medical history and directed 
physical examination.
Selective complementary tests 
(immunological, serological, 
endocrinological, electrophysi-
ological, image techniques, 
biopsy)
Medical or psychiatric disease.
Rule out CFS
There are four or more of this eight minor 
criteria:
1- Memory and concentration disturb
2- Odynophagia
3- Painful axilar or cervical adenophatias
4- Myalgias
5- Articular pain without phlogosis
6- Headache with a new pattern or 
seriousness.
7- Sleep that no improvement with rest.
8- Discomfort post effort > 24 hs.
Idiophatic chronic asthenia.
CHRONIC FATIGUE 
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visit, and then, approximately every 6 months. This scale
categorizes both the severity of the symptom and the
aggravating factors.
Daily activity/functional capacity scale is also a useful
tool. In this case the patient is asked to make a diary of all
their daily activities and periods of rest for a week.
Symptoms assessment
The easiest way to measure pain in the locomotive appara-
tus is with an Analogical Visual Scale (AVS), especially
when trying to assess the pain that a patient has experi-
enced during a given period of time [34].
To assess fatigue, one of the most used tools is the Multi-
dimensional Fatigue Inventory [35], a 20-item question-
naire that measures global, physical and mental fatigue,
and decrease in activity and motivation.
When the patients have difficulties for carrying out physi-
cal exercise it is important to quantify the degree of
impairment. The most objective methods are based on
determining the aerobic capacity of patients, usually with
spiro-ergometric tests, expired gases/heart rate are meas-
ured, and work load quantified. Other alternative meth-
ods that offer semi-quantitative measures, and are often
used, are the 6-minute running test [36], measuring the
strength of certain muscular groups, and the degree of
mobility of the column or the peripheral joints.
The assessment of disability is complex due to the fact that
the clinical diagnostic criteria have not been validated in
the medical-legal framework, to the lack of any objective
proof of existence as well the lack or low medical-legal
performance of validated instruments to quantify the dis-
ability associated with CFS. There is a big barrier for fulfill-
ing two major conditions in the assessment of the
disability, namely objective evidence of the impairment
and the absence of data corroborating the severity of the
pain [37].
Treatment
The therapeutic approach to CFS is complex and requires
a combination of different therapeutic modalities. In
recent decades, many therapies for CFS have been exam-
ined, but the only one that has demonstrated a significant
efficacy in patients diagnosed with CFS, together with
gradual physical exercise, is cognitive behaviour therapy,
which has been intensely developed in recent years [38-
40]. A 2008 Cochrane review found that 40% of patients
reported improvements in fatigue after cognitive behav-
ioural therapy compared with 26% in usual care at the
end of treatment. At follow-up, 1-7 months after treat-
ment ended, when people who had dropped out were
included, there was no significant difference between the
two groups. [41]
Cognitive therapy as a therapeutic modality for CFS com-
prises a series of techniques, based on the principles of
behaviour modification and the cognitive theory, aimed
at strengthening the modification of thoughts and behav-
iour related to the patient's symptoms and distress [42].
Most protocols developed for this treatment modality are
based on three key factors: programmed physical exercise,
control and coping with disease-associated stress, and
cognitive restructuring [43].
Regarding to prescription of appropriate exercise sched-
ules, there is no consensus for patients with CFS. How-
ever, it has been demonstrated that gradual exercise
programmes are beneficial for some patients, improving
both their physical work and the psychological and cogni-
tive aspects. The main objective of the exercise pro-
gramme is the progressive prevention of physical
deterioration and optimizing the functional capacity,
looking for an improvement of the patient's quality of life
[44].
Many pharmacological therapies have been used for treat-
ing CFS. However, there are very few publications on ran-
domised clinical trials with drugs, and the quality of the
available studies is not good [45-47]. On the other hand,
since the course of CFS is highly fluctuating, with alternat-
ing periods of improvement and deterioration, it has been
recommended that any therapeutic modality should com-
ply with several requirements to consider the study as
methodologically adequate.
Ampligen, an antiviral agent, has been used recently in the
treatment of this disease [48-50]. This agent is a stimula-
tor of interferon production, which reduces the levels of
RNasaL. Available results from clinical trials show modest
improvements, but results need to be verified. The FDA
currently considers Ampligen an experimental therapy,
and has not approved it for general use [51], although an
open clinical trial is being carried out with this drug.
Chronic fatigue syndrome in paediatric patients
It can be stated that CFS is rare in childhood and adoles-
cence: only 0.06% to 0.32% of children from 5 to 15 years
of age fulfil the US Centers for Disease Control and Pre-
vention (CDC) criteria for CFS [51].
Although the CDC criteria is mostly followed [27], differ-
ent research groups accept that, although fatigue for at
least 6 months is required to establish the diagnosis,
shorter periods of debilitating fatigue should be consid-
ered in adolescents or school-aged children [52]. Since the
adjective  debilitating  is the disease's main feature, it isBMC Psychiatry 2009, 9(Suppl 1):S1 http://www.biomedcentral.com/1471-244X/9/S1/S1
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highly likely that shorter periods of 3 months, or even 4-
6 weeks, should be considered when associated with
absenteeism. This factor is so important that the primary
care paediatrician or general practitioner (GP) should sus-
pect CFS whenever it is present, although the clinical pic-
ture does not fulfil more stringent criteria.
The Australian Clinical Guide, sponsored by the Royal
Australasian Collage of Physicians, includes issues such as
the definition of fatigue, its assessment, particular charac-
teristics when the condition affects children and adoles-
cents, and its associated symptoms. But the guide goes
beyond major and minor inclusion or exclusion criteria
[5]. In contrast with the CDC criteria, this guide empha-
sizes as a key issue the patient feeling symptomatically ill
after a minimum physical or mental effort. In addition, it
offers clear explanations for neurological and neuroendo-
crine disorders, as well as the autonomic and immune
manifestations of CFS.
The obsessive tendency to rigidly classify children and
adolescents with highly stringent criteria is inappropriate,
even though such criteria are internationally accepted.
Table 2 summarizes the differences noted in CFS between
adults and children.
Children and adolescent patients, although they do not
strictly fulfil the CDC criteria, will benefit from an early
intervention, with a substantially more adequate thera-
peutic response [53]. This fact urges primary care paedia-
tricians and GPs to make a presumptive CFS diagnosis
resulting in early intervention. Nevertheless, Davies et al
assessed the clinical presentation of CFS in children
younger than 12-year-old, based on the Royal College of
Paediatrics and Child Health criteria (less stricter criteria
compared to CDC adult criteria) and found that these
children were very disabled, with mean school attendance
of just over 40%. But, when compared to adolescent
patients, clinical assessment was very similar. In addition,
younger patients (24/26) also fullfilled the CDC criteria
[54].
In epidemiological studies including children and adoles-
cents, prevalence of 8.7 cases per 100,000 with fatigue,
and 2.7 per 100,000 people with CFS are found according
to a study published by Jordan et al [55]. It must be
assumed that, since there are no accurate and realistic cri-
teria for the diagnosis of CFS in adolescents and children,
there are no accurate epidemiological data either.
When analysing the psychological aspects in adolescents
who fulfil the CFS diagnostic criteria, more than 1/3 have
psychiatric diagnoses at the same time, particularly
depression, and less often, generalized anxiety disorder
[56]. A prospective, community-based study in the UK
found an incidence of 0.5%for CFS in 11 to 15-year-old
adolescents, using the CDC criteria, and identified anxi-
ety/depression, conduct disorder, older age and female
gender as risk factors for the development of CFS [57].
Several studies show that adolescents with CFS internalize
somatic symptoms more intensely and are more disabled
than other adolescents diagnosed with chronic diseases
with bad prognosis, such as cancer, cystic fibrosis, or juve-
nile idiopathic arthritis [58].
Prognosis
Twenty percent of patients in Bell's study [53] continue to
consider themselves ill with limitations or disability even
13 years after the onset of the syndrome; although 8% of
children find their outcome satisfactory. Although is diffi-
cult to differentiate children with CFS from those who are
just chronically tired according to the duration of symp-
toms, in this study there is no correlation between the
degree of recovery and age of diagnosis, sex, or clinical fea-
tures at presentation. The educational impact of the dis-
ease is closely related to the outcome; 23% of patients
miss school from 1 to 6 months, 8.6% from 6 to 12
months, 5.7% from 1 to 2 years, and 8% do not recover at
all after 13 years of follow-up. A follow-up study involving
28 patients, aged 7 to 17 years, highlights the need for
early recognition and diagnosis of chronic fatigue syn-
drome in young people and the importance of continuing
paediatric support to reduce symptom persistence in the
sensitive recovery period. Maintaining school attendance
Table 2: Adult/Children CFS differences
Age Fatigue Symptoms Psychiatric profile Prevalence
%
Sex
M/F
Triggering factor
Adult
20-40
>6
months
Odynophagia
Painful adenophatias
Myalgias cephalea
Post-anxiety disorders
Depression
0.006-2.5 2-3/1 Flu
Cold
Serious disease
Child
5-15
>3-6
months
Episodic tension cephalea
Recurrent abdominal pain
Tachycardia
Orthostatic hypotension
Sadness
Hyperactivity (initial phase)
Fatigue
0.06-0.32 2.5/1 Traumatism
Sport failure
Mild diseaseBMC Psychiatry 2009, 9(Suppl 1):S1 http://www.biomedcentral.com/1471-244X/9/S1/S1
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by close liaison between health and education services
both before and after diagnosis and treatment is also vital
if long-term morbidity is to be reduced. It should be noted
that 15 patients experienced difficulties when returning to
school [59]. In another study including 42 children diag-
nosed with CFS with 1 to 4 years of follow-up after the ini-
tial medical intervention, 43% considered themselves
cured, 52% improved and 5% showed no changes in their
condition [60].
The best predictor for good outcome is still the amount of
school time lost during the first 4 years of the disease.
Teachers, primary care doctors, paediatricians, psycho-
therapists and social workers, should be aware of this to
achieve the best results and meet the best life expectations
for children suffering from this syndrome.
Treatment
In adolescents, cognitive behaviour therapy combined
with other group therapies that promote treatment com-
pliance and sharing experiences or thoughts with other
adolescents is very useful, even when they do not have
identical pathologies. It must be noted that there is very
limited evidence on cognitive therapy in adolescents.
Some non-controlled studies suggest that this therapy
reduces fatigue in young people [58,61] with early inter-
vention.
When assessing therapies, it must be remembered that
exercise temporarily worsens the symptoms and the times
for rest, naps, leisure time, or outdoors activities should
be established jointly with the adolescent.
In this chronic situation, reassurance for both adolescents
and parents is the key factor that will determine the suc-
cess of the therapeutic interventions, strengthening the
self-confidence and increasing the adherence to the pre-
scribed therapies started, and avoiding the organic versus
psychiatric debate.
Chronic fatigue syndrome in healthcare
Healthcare cost associated to CFS
It is difficult to estimate the costs imposed by CFS on
healthcare. There are few studies evaluating the use of
healthcare resources by these patients [62,63].
Although many people suffering CFS continue to work
despite of their illness for economic reasons and social
prestige, this represents an annual global loss of produc-
tivity of approximately n6,900 million, or what is the
same n15,200 per patient and year. These figures are com-
parable to the losses caused by other diseases, such as
digestive system-related conditions or infectious and par-
asitic diseases [1,64], suggesting that the CFS can be
included with other chronic processes among the highest
healthcare and socioeconomic burdens.
Healthcare management
Management of CFS should start with a correct and ade-
quate diagnosis and patient care; primary care healthcare
professionals should obtain a careful medical history and
a complete physical examination. This context gives the
best thruway to the healthcare system due to its easy
access, and its knowledge and close relationship with peo-
ple.
Primary care staff should be appropriately trained, and
capable of explaining the problem, as well as the available
therapeutic options to the patients [5].
After the initial diagnostic suspicion, and although the
burden of patients' follow-up can be perfectly accom-
plished in the primary care context, it is recommended
that patients are referred to a second level of specialised
care for confirmation of the diagnosis and treatment guid-
ance. Since in CFS medical specialities are involved in care
and treatment (rheumatology, internal medicine, psychi-
atry, etc.), such specialists should also receive adequate
training. Cooperation and coordination between primary
and specialised care is basic for the correct management of
CFS. Occasionally, the intervention of the physiotherapist
or psychologist in the treatment is also necessary, and ade-
quate training should also be offered to these healthcare
professionals.
In addition to a timely and appropriate diagnosis, patients
with CFS usually require individualized management pro-
grams, as well as long-term follow-up. Although health-
care professionals are mostly responsible for the latter, the
collaboration of the patient's relatives and friends is also
essential. It is therefore necessary to train them, with the
objective of reducing the patient's anxiety and strengthen-
ing the very valuable therapeutic alliance [5]. All this can
considerably improve the prognosis of the condition. The
particular social context of each patient and the functional
repercussion should also be recognized and assessed [65].
Finally, as CFS is not well known, the contribution of
enough funds for research is also necessary, and the regu-
lated identification and management of patients or the
creation of adequate records by the healthcare system
would be a very useful intervention.
Legal aspects
Giving advice to a person with CFS in medical-legal mat-
ters can be very complex and should be done by a quali-
fied, experienced specialist. The notion of "permanent"
disability is problematic, as many people with CFS gradu-
ally improve. In patients seriously disabled, who haveBMC Psychiatry 2009, 9(Suppl 1):S1 http://www.biomedcentral.com/1471-244X/9/S1/S1
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been unable to work for more than five years, the proba-
bility of significant improvement in 10 years is less than
10-20%. This can be considered "permanent disability" in
medical-legal terms [5].
As explained above, CFS is a highly disabling condition in
some patients, frequently requiring legal support for man-
aging possible social aids, handicaps or even disabilities.
Ancillary personnel or social workers in healthcare centres
and city councils should provide information and advice
to the patients when they need it. It will also be necessary
for the administrators to adapt the help to each case and
the training of their personnel to become familiar with the
CFS, avoiding excessive litigation when looking for social
aids.
Educational aspects
A good interdisciplinary team for the diagnosis and treat-
ment of CFS, together with personalised care will enhance
the patient's improvement. The person suffering the dis-
ease wants to know what can be done to improve and
adapt to the upcoming changes.
Patient education should always be supported by the
healthcare sector, and may be grouped in two different
categories: therapeutic and related to the patient's social
setting.
Conclusion
CFS is a chronic process that becomes a social disease due
to the incapacity that it causes in the person who suffers to
continue to fulfill their work, social and family responsi-
bilities.
The specific characteristics of the symptomatology of
patients with CFS require a rapid adaptation of the educa-
tional, healthcare and social systems to prevent the prob-
lems derived from current systems. The lack of adequate
care for these issues is causing serious difficulties, short-
ages and even rejections in areas as essential as education,
social integration and coexistence, work insertion, and
integrated care and medical management.
At present, no curative treatment exists for patients with
CFS. Treatment objectives must be focused on improving
the clinical manifestations, maintaining the functional
capacity and quality of life, and developing a tailored pro-
gramme, providing each patient with the maximum per-
ception of improvement. Patients with CFS require
multidisciplinary management due to the multiple and
different issues affecting them. This multidisciplinary
management requires coordination between the different
specialists, which leads to the need for the existence of an
Action Protocol to establish the intervention procedure
according to the needs of each patient.
As mentioned above, CFS is disabling in some patients. In
these cases, all the support measures recognised in current
legislation should be applied. The most important issues
to overcome are the difficulties of access to employment,
timetable flexibility and ergonomic assessments in order
to adapt the work post.
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